Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776026 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| SCHEMBL29561050 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| SCHEMBL22776267 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| SCHEMBL30965947 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| SCHEMBL22776130 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| SCHEMBL30965919 | 0.94 | TRPM8 (0.61) | TRPM8CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL22776777 | 0.92 | TRPM8 (0.60) | TRPM8CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL29271817 | 0.91 | TRPM8 (0.60) | TRPM8CHRM3KCNH2ESR1ESR2 | |
| Formic Acid SCHEMBL22776311 | 0.89 | CHRM3 (0.59) | TRPM8CHRM3KCNH2 | |
| SCHEMBL3057164 | 0.85 | TRPM8 (0.71) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | TRPM8 3405/4885CHRM3 4360/4885KCNH2 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.